Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RVNC
  • CUSIP: N/A
  • Web:
  • Market Cap: $736.58 million
  • Outstanding Shares: 30,819,000
Average Prices:
  • 50 Day Moving Avg: $23.75
  • 200 Day Moving Avg: $22.58
  • 52 Week Range: $12.35 - $28.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.13
  • P/E Growth: -0.57
Sales & Book Value:
  • Annual Revenue: $300,000.00
  • Price / Sales: 2,475.79
  • Book Value: $5.24 per share
  • Price / Book: 4.60
  • EBIDTA: ($89,740,000.00)
  • Net Margins: -32,936.67%
  • Return on Equity: -55.21%
  • Return on Assets: -47.75%
  • Current Ratio: 7.94%
  • Quick Ratio: 7.94%
  • Average Volume: 171,227 shs.
  • Beta: 1.6
  • Short Ratio: 23.45

Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Thursday, August, 3rd. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.93) by $0.03. The business earned $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. Revance Therapeutics's revenue was up .0% on a year-over-year basis. During the same period last year, the business posted ($0.88) EPS. View Revance Therapeutics' Earnings History.

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?

4 analysts have issued 12-month price targets for Revance Therapeutics' stock. Their forecasts range from $28.00 to $50.00. On average, they expect Revance Therapeutics' stock price to reach $37.00 in the next year. View Analyst Ratings for Revance Therapeutics.

What are analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (9/19/2017)
  • 2. Cantor Fitzgerald analysts commented, "Today Revance announced that Mark Foley has been appointed to the Board of Directors, effective 9/5/17." (9/6/2017)

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:

  • Angus Charles Russell, Independent Chairman of the Board
  • L. Daniel Browne, Co-Founder, President, Chief Executive Officer, Director
  • Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer
  • Abhay Joshi Ph.D., Chief Operating Officer
  • Todd E. Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics
  • Robert F. Byrnes, Independent Director
  • Ronald W. Eastman, Independent Director
  • Julian S. Gangolli, Independent Director
  • Phyllis I. Gardner M.D., Independent Director
  • Philip J. Vickers, Independent Director

Who owns Revance Therapeutics stock?

Revance Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (11.98%), Franklin Resources Inc. (11.15%), Bank of New York Mellon Corp (6.87%), Vanguard Group Inc. (3.08%), Canada Pension Plan Investment Board (1.93%) and State Street Corp (1.47%). Company insiders that own Revance Therapeutics stock include Arthur Peter Bertolino, Curtis Ruegg, L Daniel Browne and Lauren P Silvernail. View Institutional Ownership Trends for Revance Therapeutics.

Who sold Revance Therapeutics stock? Who is selling Revance Therapeutics stock?

Revance Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wells Fargo & Company MN, Paradigm Asset Management Co. LLC, TIAA CREF Investment Management LLC, Suffolk Capital Management LLC, Granite Investment Partners LLC, Rothschild Asset Management Inc. and Victory Capital Management Inc.. Company insiders that have sold Revance Therapeutics stock in the last year include L Daniel Browne and Lauren P Silvernail. View Insider Buying and Selling for Revance Therapeutics.

Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?

Revance Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Jennison Associates LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., PointState Capital LP, Vanguard Group Inc., QS Investors LLC and Northern Trust Corp. View Insider Buying and Selling for Revance Therapeutics.

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of Revance Therapeutics stock can currently be purchased for approximately $24.10.

MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.00 (53.53% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Cantor FitzgeraldReiterated RatingBuy$50.00LowView Rating Details
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$34.00MediumView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetBuy$28.00LowView Rating Details
6/8/2017AegisReiterated RatingBuy$36.00MediumView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
6/14/2016SunTrust Banks, Inc.Lower Price TargetBuy$46.00 -> $22.00N/AView Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Revance Therapeutics (NASDAQ:RVNC)
Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Earnings History by Quarter for Revance Therapeutics (NASDAQ RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.93)($0.90)$0.05 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
2017 EPS Consensus Estimate: ($3.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.85)($0.80)($0.83)
Q2 20172($0.99)($0.98)($0.99)
Q3 20172($1.02)($1.02)($1.02)
Q4 20172($0.99)($0.95)($0.97)
(Data provided by Zacks Investment Research)


Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 18.86%
Institutional Ownership Percentage: 89.32%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2017L Daniel BrowneCEOSell22,800$22.76$518,928.00View SEC Filing  
5/24/2017L Daniel BrowneCEOSell19,713$20.35$401,159.55View SEC Filing  
5/22/2017L Daniel BrowneCEOSell12,287$20.20$248,197.40View SEC Filing  
5/22/2017Lauren P SilvernailCFOSell1,793$20.20$36,218.60View SEC Filing  
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Revance Therapeutics (NASDAQ:RVNC)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
DateHeadline logoRevance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference - September 20 at 8:34 AM logoETFs with exposure to Revance Therapeutics, Inc. : September 19, 2017 - September 20 at 8:34 AM logoRevance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 - September 19 at 7:22 AM logoZacks Investment Research Lowers Revance Therapeutics, Inc. (RVNC) to Hold - September 16 at 12:24 PM logoZacks Investment Research Upgrades Revance Therapeutics, Inc. (RVNC) to "Buy" - September 9 at 6:22 PM logoRevance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of "Buy" from Analysts - September 8 at 2:44 AM logoRevance Therapeutics, Inc. (RVNC) Downgraded to "Hold" at Zacks Investment Research - September 7 at 8:20 AM logoCantor Fitzgerald Reaffirms Buy Rating for Revance Therapeutics, Inc. (RVNC) - September 6 at 1:28 PM logoRevance Appoints Mark Foley to its Board of Directors - September 6 at 7:51 AM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 1, 2017 - September 2 at 8:17 AM logoRevance to Participate in the 2017 Wells Fargo Securities Healthcare Conference - August 31 at 9:38 AM logoRevance Therapeutics, Inc. (RVNC) Rating Increased to Buy at Zacks Investment Research - August 30 at 6:28 AM logoRevance Therapeutics, Inc. (RVNC) Stock Rating Lowered by Zacks Investment Research - August 27 at 12:28 AM logoRevance Therapeutics, Inc. (RVNC) CEO L Daniel Browne Sells 22,800 Shares - August 25 at 10:28 PM logo$80,000.00 in Sales Expected for Revance Therapeutics, Inc. (RVNC) This Quarter - August 25 at 7:48 AM logoRevance Therapeutics, Inc. (RVNC) Upgraded at Zacks Investment Research - August 22 at 11:22 AM logoJMP Securities Initiates Coverage on Revance Therapeutics, Inc. (RVNC) - August 22 at 9:08 AM logoBidaskClub Upgrades Revance Therapeutics, Inc. (RVNC) to "Hold" - August 18 at 7:35 PM logoRevance Therapeutics: An Undervalued Botox Competitor - August 17 at 4:17 PM logoRevance Therapeutics, Inc. (RVNC) Stock Rating Upgraded by Zacks Investment Research - August 15 at 9:56 AM logoRevance Therapeutics, Inc. (RVNC) Given Consensus Recommendation of "Hold" by Brokerages - August 14 at 2:44 AM logoZacks Investment Research Lowers Revance Therapeutics Inc (NASDAQ:RVNC) to Hold - August 12 at 5:08 PM logoFY2017 Earnings Forecast for Revance Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:RVNC) - August 10 at 9:32 AM logoRevance Therapeutics, Inc. (NASDAQ:RVNC) Posts Earnings Results, Beats Estimates By $0.03 EPS - August 5 at 5:08 PM logoEdited Transcript of RVNC earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 5 at 6:46 AM logoRevance Releases Second Quarter 2017 Results - August 4 at 7:50 AM logoRevance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : July 31, 2017 - August 1 at 6:09 AM logoBrokers Offer Predictions for Revance Therapeutics, Inc.'s FY2017 Earnings (NASDAQ:RVNC) - July 26 at 11:16 AM logoRevance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017 - July 25 at 6:22 AM logoRevance Therapeutics, Inc. (RVNC) Now Covered by Cantor Fitzgerald - July 20 at 7:08 PM logoRevance Therapeutics, Inc. (RVNC) Receives Consensus Rating of "Hold" from Brokerages - July 20 at 6:26 PM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : July 17, 2017 - July 17 at 3:35 PM logoCommit To Purchase Revance Therapeutics At $20, Earn 11.6% Annualized Using Options - July 8 at 7:11 PM logoRevance Therapeutics, Inc. (NASDAQ:RVNC) Raised to "Buy" at BidaskClub - July 6 at 7:50 PM logoBrokers Set Expectations for Revance Therapeutics, Inc.'s FY2017 Earnings (RVNC) - June 19 at 7:20 AM logoPositive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery - June 16 at 9:33 AM logoRevance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of "Hold" from Brokerages - June 13 at 6:26 PM logoRevance Therapeutics Inc (RVNC) Rating Increased to Hold at ValuEngine - June 9 at 3:22 PM logoRevance Therapeutics Inc (RVNC) Earns Buy Rating from Aegis - June 8 at 9:02 AM logoRevance Therapeutics (RVNC) Reports Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial - June 6 at 9:57 PM logoRevance Therapeutics (RVNC) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 6 at 9:57 PM logoRevance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial - June 5 at 9:41 PM logoRevance Therapeutics Inc (RVNC) Short Interest Up 4.0% in May - May 31 at 8:44 AM logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : May 26, 2017 - May 27 at 4:06 AM logoRevance Therapeutics Inc (RVNC) CEO L Daniel Browne Sells 19,713 Shares - May 24 at 10:57 PM logoRevance Therapeutics Inc (RVNC) CFO Lauren P. Silvernail Sells 1,793 Shares - May 24 at 10:56 PM logoRevance Therapeutics Inc (RVNC) CEO Sells $248,197.40 in Stock - May 24 at 10:56 PM logoRevance Therapeutics (RVNC) Presents On Phase 2 Cervical Dystonia 24-Week Results - Slideshow - May 23 at 7:01 PM logoRevance Therapeutics Inc (RVNC) Stock Rating Reaffirmed by Aegis - May 19 at 9:36 PM logoRevance Therapeutics Inc (RVNC) Receives Average Recommendation of "Buy" from Brokerages - May 19 at 7:30 PM



Revance Therapeutics (RVNC) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff